The chemical class designated as LST1 Activators consists of a diverse array of compounds that potentially modulate the activity of LST1 (Leukocyte-Specific Transcript 1), a protein implicated in immune system responses and inflammatory processes. This class is primarily composed of molecules that activate or influence signaling pathways in the immune system, which, in turn, may have an indirect impact on LST1 activity. These compounds include various agonists of Toll-like receptors (TLRs) and other molecules involved in innate immune signaling. For instance, compounds like PMA (Phorbol 12-Myristate 13-Acetate) and LPS (Lipopolysaccharides) are known to activate specific signaling pathways such as Protein Kinase C and Toll-like receptors, respectively. The activation of these pathways can potentially influence the activity of LST1, given its role in modulating immune responses. Similarly, TLR agonists like CpG Oligodeoxynucleotides, Imiquimod, Poly(I:C), and R848 target different aspects of the immune system's response to external stimuli, potentially impacting the activity of LST1 through their engagement with these critical receptors.
Additionally, this chemical class includes compounds that stimulate TLRs involved in recognizing specific pathogen-associated molecular patterns, such as Flagellin, Gardiquimod, Resiquimod, Pam3CSK4, and Muramyl Dipeptide. Each of these compounds has a unique mechanism of action, targeting different TLRs or other immune receptors, which can indirectly influence LST1 activity. For example, Flagellin, as a TLR5 agonist, may impact LST1 activity in bacterial immune responses, while Gardiquimod and Resiquimod, as TLR7/8 agonists, could affect LST1 in the context of viral defense mechanisms. The activation of these receptors and subsequent signaling cascades highlights the potential of these compounds to modulate immune and inflammatory responses where LST1 is involved. The LST1 Activators class, therefore, represents a collection of compounds that, through their varied roles in activating or influencing immune signaling pathways, have the capacity to indirectly affect the activity of the LST1 protein. This class exemplifies the intricate interplay within the immune system, where modulation of specific receptors and signaling molecules can have broader implications for the regulation of proteins involved in immune responses.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates Protein Kinase C, could influence signaling pathways involving LST | ||||||
Lipopolysaccharide, E. coli O55:B5 | 93572-42-0 | sc-221855 sc-221855A sc-221855B sc-221855C | 10 mg 25 mg 100 mg 500 mg | $98.00 $171.00 $425.00 $1560.00 | 12 | |
Can activate Toll-like receptors, potentially impacting LST1 activity in immune response. | ||||||
Imiquimod | 99011-02-6 | sc-200385 sc-200385A | 100 mg 500 mg | $67.00 $284.00 | 6 | |
TLR7 agonist, could enhance pathways involving LST1 in immune response. | ||||||
Polyinosinic-polycytidylic acid potassium salt | 31852-29-6 | sc-202767 | 5 mg | $198.00 | ||
TLR3 agonist, might influence LST1 activity in antiviral responses. | ||||||
R-848 | 144875-48-9 | sc-203231 sc-203231A sc-203231B sc-203231C | 5 mg 25 mg 100 mg 500 mg | $102.00 $306.00 $510.00 $1559.00 | 12 | |
Can activate TLR7/8, potentially impacting LST1 in immune signaling. | ||||||
Gardiquimod | 1020412-43-4 | sc-221663 sc-221663A sc-221663B sc-221663C sc-221663D sc-221663E sc-221663F | 25 mg 50 mg 100 mg 250 mg 5 g 10 g 25 g | $157.00 $282.00 $516.00 $1177.00 $20138.00 $32779.00 $70753.00 | 1 | |
TLR7 agonist, might impact LST1 in immune response pathways. | ||||||
Pam3Cys-Ser-(Lys)4, Hydrochloride | 112208-00-1 | sc-507471 | 2 mg | $550.00 | ||
TLR1/2 agonist, could influence LST1 activity in immune responses. | ||||||